Clark Butler
Family Medicine · Jefferson City, MONPI 1841776630
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 326 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,849 and has fallen 97.5% since, to $45 in 2025. Among family medicine clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$720
- AstraZeneca$672
- AbbVie$667
- Novo Nordisk$571
- Amgen$400
- Otsuka America Pharmaceutical, Inc.$271
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,215100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 54 | $720 |
| AstraZeneca | 26 | $672 |
| AbbVie | 52 | $667 |
| Novo Nordisk | 48 | $571 |
| Amgen | 23 | $400 |
| Otsuka America Pharmaceutical, Inc. | 13 | $271 |
| Merck | 13 | $194 |
| Teva Pharmaceuticals USA, Inc. | 8 | $165 |
| Nevro Corp. | 3 | $150 |
| Bayer | 9 | $141 |
| Novartis | 9 | $124 |
| Nestle Healthcare Nutrition Inc. | 6 | $118 |
| Boehringer Ingelheim | 7 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $97 |
| Lundbeck LLC | 4 | $74 |
| Dexcom, Inc. | 4 | $73 |
| Sumitomo Pharma America, Inc. | 5 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Johnson & Johnson | 4 | $62 |
| Sunovion Pharmaceuticals Inc. | 5 | $60 |
| Exact Sciences | 3 | $47 |
| Abbott | 3 | $46 |
| Innovation Technologies Inc | 1 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $36 |
| Ardelyx, Inc. | 2 | $35 |
| Pfizer | 2 | $32 |
| Boston Scientific | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Sobi, Inc | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,215 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 138 | $148,471 |
| JardianceEmpagliflozin | 104 | $111,793 |
| FarxigaDapagliflozin Propanediol | 124 | $105,476 |
| EliquisApixaban | 115 | $89,673 |
| VraylarCariprazine Hcl | 50 | $72,191 |
| Humira(Cf)Adalimumab | 11 | $71,628 |
| TrulicityDulaglutide | 44 | $53,028 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $52,740 |
| Tresiba Flextouch U-200Insulin Degludec | 53 | $49,924 |
| XareltoRivaroxaban | 76 | $46,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $37,880 |
| JanuviaSitagliptin Phosphate | 37 | $33,505 |
| EntrestoSacubitril/Valsartan | 36 | $33,054 |
| LinzessLinaclotide | 45 | $27,037 |
| Spiriva RespimatTiotropium Bromide | 33 | $22,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Humira(Cf), Linzess | $667 | $170,856106 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $672 | $162,361209 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $110 | $150,470170 claims |
| Novo NordiskOzempic | $571 | $148,471138 claims |
| PfizerEliquis, Nurtec Odt | $32 | $100,988126 claims |
| Lilly USA, LLCTrulicity | $720 | $53,02844 claims |
| Johnson & JohnsonXarelto | $62 | $46,15776 claims |
| MerckJanuvia | $194 | $33,50537 claims |
| NovartisEntresto | $124 | $33,05436 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $73 | $16,16221 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $26 | $6,21613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Jefferson City
- George CarrJefferson City$25K
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.